WO2010074656A1 - Monoclonal antibodies specific to the fusion peptide from hemagglutinin from influenza a viruses and uses thereof - Google Patents

Monoclonal antibodies specific to the fusion peptide from hemagglutinin from influenza a viruses and uses thereof Download PDF

Info

Publication number
WO2010074656A1
WO2010074656A1 PCT/SG2008/000499 SG2008000499W WO2010074656A1 WO 2010074656 A1 WO2010074656 A1 WO 2010074656A1 SG 2008000499 W SG2008000499 W SG 2008000499W WO 2010074656 A1 WO2010074656 A1 WO 2010074656A1
Authority
WO
WIPO (PCT)
Prior art keywords
binding protein
influenza
antibody
virus
monoclonal antibody
Prior art date
Application number
PCT/SG2008/000499
Other languages
French (fr)
Inventor
Prabakran Mookkan
Nayana Prabhu Padubidhri
Sumathy Velumani
Hwei-Sing Jimmy Kwang
Original Assignee
Temasek Life Sciences Laboratory Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Temasek Life Sciences Laboratory Limited filed Critical Temasek Life Sciences Laboratory Limited
Priority to AU2008365616A priority Critical patent/AU2008365616A1/en
Priority to US13/141,160 priority patent/US8540995B2/en
Priority to PCT/SG2008/000499 priority patent/WO2010074656A1/en
Priority to SG2011045911A priority patent/SG172333A1/en
Priority to CN2008801327259A priority patent/CN102292350A/en
Priority to EP08879238A priority patent/EP2379591A4/en
Priority to TW098144590A priority patent/TW201028166A/en
Publication of WO2010074656A1 publication Critical patent/WO2010074656A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/11—Orthomyxoviridae, e.g. influenza virus

Definitions

  • This invention relates to methods and products for the diagnosis, surveillance, prevention, and treatment of influenza A virus infections in animals and humans. More particularly, the invention relates to antibodies and related binding proteins for the detection, prevention and treatment of influenza A viruses.
  • the monoclonal antibodies and related binding proteins of the invention are useful for the treatment of the highly pathogenic H5 subtypes of avian influenza virus (AIV).
  • H5 strains are currently causing major morbidity and mortality in poultry populations across Asia, Europe, and Africa and have caused 385 confirmed human infections, with a fatality rate of 63.11 % (1 , 2) 1 .
  • Preventive and therapeutic measures against circulating H5N1 strains have received a lot of interest and effort globally to prevent another pandemic outbreak.
  • Influenza A virus poses a challenge as it
  • a bibliography is provided at the end of the disclosure. rapidly alters its appearance to the immune system by antigenic drift (mutating) and antigenic shift (exchanging its components) (3).
  • the current combat strategies against influenza include vaccination and anti-viral drug treatment, with vaccination being the preferred option.
  • the annual influenza vaccine aims to stimulate the generation of anti-hemagglutinin neutralizing antibodies, which confer protection against homologous strains.
  • the current vaccines have met with varying degrees of success (4).
  • the fact that these strategies target the highly variable HA determinant and predicting the major HA types that pose the next epidemic threat can impose limitations to the current viral strategy. In the absence of an effective vaccine, therapy is the mainstay of control of influenza infection.
  • H5N1 viruses are known to be resistant to the M2 ion channel inhibitors (5, 6). Newer strains of H5N1 viruses are being isolated which are even resistant to the neuraminidase inhibitors (Oseltamivir and Zanamivir) (3, 7). The neuraminidase inhibitors also may need high doses and prolonged treatment (3, 8). Hence, alternative strategies for treatment of influenza are warranted. Recently, passive immunotherapy using monoclonal antibodies are being viewed upon as a viable treatment option (9).
  • Testing during an outbreak of an acute respiratory disease can determine if influenza is the cause.
  • testing of selected patients presenting with respiratory illnesses compatible with influenza can help establish whether influenza is present in a specific patient population and help health-care providers determine how to use their clinical judgment for diagnosing and treating respiratory illness.
  • a rapid influenza test helps in the determination of whether to use an antiviral medication.
  • Some tests, such as a viral culture, reverse-transcriptase polymerase chain reaction (RT-PCR) and serological testing are the routine methods, but results may not be available in a timely manner to assist clinicians. At present, most of the rapid diagnostic tests currently in use are monoclonal antibody-based immunoassays.
  • Immunofluorescence is the alternative to rapid influenza diagnostic tests which can be used in many hospital laboratories and generally can yield test results in 2-4 hours. Above all, specific monoclonal antibody generation is fundamental to most currently used rapid, sensitive and cost-effective diagnostic methods.
  • Hemagglutinin (HA) is the most variable gene of the influenza virus and also the most promising target for generating antibodies. It is synthesized as a precursor polypeptide HAO, which is post-translationally cleaved to two polypeptides HA1 and HA2 linked by a disulphide bond. Monoclonal antibodies against the HA1 are known to neutralize the infectivity of the virus and hence provide good protection against infection (10).
  • the HA2 N-terminal fusion peptide is the most highly conserved region in HA among all influenza A subtypes (11). This HA2 polypeptide is responsible for the fusion of the virus and the host endosomal membrane during the entry of the virus into the cell (12). Part of the HA2 N-terminal fusion peptide is exposed as a surface loop in the precursor molecule (13, 14). As most HA subtypes are cleaved by extracellular enzymes, this surface loop is accessible to antibody on HAO expressed in the plasma membrane of infected host cells (15).
  • An object of this invention is to provide monoclonal antibodies (mAbs) and related binding proteins that bind to influenza A virus, particularly to the HA2 polypeptide of influenza A viruses.
  • the HA2 polypeptide is highly conserved in influenza A subtypes.
  • mAbs that specifically recognize the HA2 polypeptide will recognize all influenza A subtypes.
  • the specificity of these monoclonal antibodies provides a basis for effective prophylactic and therapeutic agents.
  • a monoclonal antibody that is specific for conformational epitopes of the influenza A hemagglutinin glycoprotein is provided.
  • the HA2 polypeptide represents the highly conserved region of the hemagglutinin across influenza A strains.
  • the monoclonal antibody binds specifically to the antigenically conserved fusion peptide of HA2 and is effective in providing cross-clade protection against influenza A infections.
  • MAbs that target conserved epitopes are useful for detecting the virus in tissues which have not been pre-treated, such as frozen tissue specimens and other biological tissues and fluids.
  • a mAb designated 1C9 targets an epitope on HA2 of influenza A virus, for example, AIV subtypes.
  • this invention comprises a binding protein having substantially the immunological binding characteristics for a conformational HA2 epitope as those of mAb 1 C9.
  • the invention comprises a method for detecting influenza A virus in a specimen which comprises detecting the binding of the HA2 polypeptide with a mAb or binding protein having substantially the immunological binding characteristics of mAb 1C9.
  • the invention relates to immunofluorescence assays, immunohistochemical assays and other methods that utilize such binding proteins.
  • kits for the detection of influenza A virus which comprise binding proteins having substantially the immunological binding characteristics of mAb 1C9.
  • the invention further relates to methods of treating subjects infected with influenza A virus strain, which comprise administering to such subjects effective amounts of one or more recombinant monoclonal antibodies or binding proteins or fragments thereof having substantially the immunological binding characteristics of mAb 1C9.
  • the invention further relates to methods of providing cross-clade protection against infection against the fusion peptide of the HA2 glycoprotein which comprise administering to such subjects effective amounts of one or more recombinant monoclonal antibodies or binding proteins or fragments thereof having substantially the immunological binding characteristics of mAb 1C9.
  • Figures 1a-1c show the epitope mapping of monoclonal antibodies 1C9.
  • Figure 1a represents gene-segments coding for fragments 1 to 14 of HA2.
  • Western Blotting analyses of the monoclonal antibodies were performed to map their respective epitopes (the numbers indicate the amino acid number on HAO).
  • Figure 1b Western blot analysis of the 14 fragments: mAb1C9 was used as the primary antibody. Lane 1 had the protein molecular weight marker. Lanes 2 and 18 show recombinant HA2 gp, Lane 3 shows HA2 from whole virus, Lanes 4 to 17 show the 14 fragments. Only fragments 1 to 6 show positive results, while fragments 7 to 14 show negative results. The samples were run on three different gels but processed identically.
  • Figure 1c The results of Western blot analysis of point mutants also expressed as histidine-fusion peptides.
  • the membrane was developed using ECL reagents. The analysis was carried out to determine the amino acid sequence of the epitope for mAb 1C9.
  • Lanes 1 and 16 had the protein molecular weight marker.
  • Lanes 2 and 17 show the wild-type fragment 1.
  • Lanes 3 to 15, 18 and 19 were loaded with the over expressed point mutants. Positive results were seen only in lanes with wild type fragment 1 , point mutants I340A (12), E341A (13), G342A (14), G343A (15), W344A (18) and Q345A (19), indicating the absence of the role of the respective amino acids in binding to the HA2 gp.
  • Photomicrographs of hematoxylin- and eosin- stained lung sections of mice infected with Clade 2.1 H5N1 virus at 5 days post challenge a) Normal morphology seen in uninfected mice, b) infected and untreated mice, c) infected mice treated with 5mg/kg of 1C9 at 24 hour post challenge, d) infected mice treated with 10 mg/kg of 1C9 at 24 hour post challenge, e) infected mice treated with 5 mg/kg of 1C9, 24 hours prior to viral challenge, f) infected mice treated with 10 mg/kg of 1C9, 24 hours prior to viral challenge.
  • FIG 4a Protection of mice from lethal H5N1 viral challenge.
  • Each group of mice was intra-peritoneally treated with 10 mg/kg, 5 mg/kg or 0 mg/kg (PBS) of 1C9 mAb after 1 day post viral challenge with mouse-adapted Indonesian HPAI H5N1 (A/Vietnam/1203/04-Clade 1.0) virus. Mice were monitored for survival throughout a 14 day observation period. The results are expressed in terms of percent survival.
  • Figures 4b and 4c Protection of mice from lethal H5N1 viral challenge.
  • mice Each group of mice was intra-peritoneally treated with 10 mg/kg, 5 mg/kg or 0 mg/kg (PBS) of 1C9 mAb after 1 day post viral challenge with mouse-adapted Indonesian HPAI H5N1 (A/TLL013/06-Clade 2.1 ) virus. Mice were monitored for survival (Fig. 4b) and weight loss (Fig. 4c) throughout a 14 day observation period. The results are expressed in terms of percent survival and percent body weight (at the beginning of the trial), respectively (* represents no survival of any animals in the group).
  • Figure 4d Protection of mice from lethal H5N1 viral challenge.
  • Each group of mice were intra-peritoneally treated with 10 mg/kg, 5 mg/kg or 0 mg/kg (PBS) of 1C9 mAb after 3 day post viral challenge with mouse-adapted Indonesian HPAI H5N1 (A/Vietnam/1203/04-Clade 1.0) virus. Mice were monitored for survival throughout a 14 day observation period. The results are expressed in terms of percent survival.
  • Figures 4e and 4f Protection of mice from lethal H5N1 viral challenge.
  • mice were intraperitoneal ⁇ treated with 10 mg/kg, 5 mg/kg or 0 mg/kg (PBS) of 1C9 mAb after 3 day post viral challenge with mouse-adapted Indonesian HPAI H5N1 (A/TLL013/06-Clade 2.1 ) virus.
  • Mice were monitored for survival (Fig. 4e) and weight loss (Fig. 4f) throughout a 14 day observation period. The results are expressed in terms of percent survival and percent body weight (at the beginning of the trial), respectively (* represents no survival of any animals in the group).
  • Figure 5a Protection of mice from lethal H5N1 viral challenge.
  • mice were intra-peritoneally pre-treated with 10 mg/kg, 5 mg/kg or 0 mg/kg (PBS) of 1C9 mAb on 1 day before challenge with mouse-adapted Indonesian HPAI H5N1 (A/Vietnam/1203/04-Clade 1.0) virus. Mice were monitored for survival throughout a 14 day observation period. The results are expressed in terms of percent survival. Figures 5b and 5c. Protection of mice from lethal H5N1 viral challenge. Each group of mice were pre-treated with 10 mg/kg, 5 mg/kg or 0 mg/kg (PBS) of 1C9 mAb on 1 day before challenge with mouse-adapted Indonesian HPAI H5N1 (A/TLL013/06-Clade 2.1 ) virus.
  • FIG. 5b mice were monitored for survival (Fig. 5b) and weight loss (Fig. 5c) throughout a 14 day observation period. The results are expressed in terms of percent survival and percent body weight (at the beginning of the trial), respectively (* represents no survival of any animals in the group).
  • Figure 6a shows the measurement of viral loads by qPCR , in the lungs of pre-treated mice and mice challenged with virus. Each group of mice was pre- treated with 10 mg/kg, 5 mg/kg or 0 mg/kg (PBS) of 1C9 mAb on 1 day before challenge with mouse-adapted Indonesian HPAI H5N1 (A/TLL013/06-Clade 2.1) virus. The viral loads were measured in the lungs of the infected animals on days 2, 4 and 10 post challenge.
  • FIG. 6b shows the measurement of viral loads by qPCR , in the lungs of infected animals challenged with virus and subsequently treated.
  • Each group of mice was challenged with mouse-adapted Indonesian HPAI H5N1 (A/TLL013/06-Clade 2.1 ) virus and treated with 10 mg/kg, 5 mg/kg or 0 mg/kg (PBS) of 1C9 mAb 1 day after challenge.
  • the viral loads were measured in the lungs of the infected animals on days 2, 4 and 10 post challenge.
  • the results are expressed in terms of mean value of log (number of copies)/400ng of RNA ⁇ S. D. (# represents no survival of any animals in the group and & represents undetectable viral numbers; *** p ⁇ 0.01 ).
  • the present invention is directed to mAbs and related antigen-binding proteins that bind specifically to the HA2 N-terminal fusion peptide of influenza A virus.
  • the mAb or related antigen binding protein possesses the immunological binding characteristics of mAb 1C9, as produced by hybridoma 1C9, deposited with the American Type Culture Collection (ATCC), VA, USA, under the terms of the Budapest Treaty on November 6, 2007, and assigned Accession Number PTA-8759.
  • the invention further embodies this hybridoma which provides a continuous source of the mAbs and binding proteins of the invention.
  • the invention further relates to methods for the detection and diagnosis of influenza A infection and assay kits that comprise the mAbs or binding proteins of the invention.
  • the invention further relates to methods of treating a subject infected with an influenza A virus through the administration of effective amounts of an antibody fragment or recombinant antibody comprising an antibody or related binding protein of the invention.
  • the subject is infected with an H5 AIV.
  • the antibody of this invention also can be administered to subjects on the advent of a possible influenza pandemic as a precautionary measure. In this instance, effective amounts of antibody to be administered are about half of the amounts used to treat influenza A virus infections.
  • immunological binding characteristics of a mAb or related binding protein, in all of its grammatical forms, refers to the specificity, affinity and cross-reactivity of the mAb or binding protein for its antigen.
  • binding protein@ refers to a protein, including those described below, that includes the antigen binding site of a mAb of the present invention or a mAb having the immunological binding characteristics of a mAb of the present invention.
  • the present invention advantageously provides methods for preparing monoclonal antibodies having the binding characteristics of mAb 1C9 by immunizing an animal with an H5N1 virus (A/goose/Guangdong/97). Any such antigen can be used as an immunogen to generate antibodies with the desired immunological binding characteristics.
  • Such antibodies include, but are not limited to, monoclonal antibodies, chimeric antibodies, single chain antibodies, Fab fragments and proteins comprising the antigen binding sequence of mAb 1 C9.
  • the mAb of the present invention can be produced by any technique that provides for the production of antibody molecules by continuous cell lines in culture. Such methods include, but are not limited to, the hybridoma technique originally developed in 1975 by Kohler and Milstein (Nature 256:495-497), as well as the trioma technique, the human B-cell hybridoma technique (Kozbor et al., 1983, Immunology Today 4:72) and the EBV-hybridoma technique to produce human monoclonal antibodies (Cole et al., in Monoclonal Antibodies and Cancer Therapy Alan R. Liss, Inc., pp 77-96 (1985)).
  • Chimeric antibodies are those that contain a human Fc portion and a murine (or other non-human) Fv portion.
  • Humanized antibodies are those in which the murine (or other non-human) complementarity determining regions (CDR) are incorporated into a human antibody. Both chimeric and humanized antibodies are monoclonal. Such human or humanized chimeric antibodies are preferred for use in in vivo diagnosis or therapy of human diseases or disorders.
  • Such antibody fragments can be generated from any of the polyclonal or monoclonal antibodies of the invention.
  • screening for the desired antibody can be accomplished by techniques known in the art, e.g., radioimmunoassay, ELISA (enzyme-linked immunosorbent assay), "sandwich” immunoassays, immunoradiometric assays, gel diffusion precipitin reactions, immunodiffusion assays, in situ immunoassays (using colloidal gold, enzyme or radioisotope labels, for example), western blots, precipitation reactions, agglutination assays (e.g., gel agglutination assays, hemagglutination assays), immunofluorescence assays and Immunoelectrophoresis assays, etc.
  • radioimmunoassay e.g., ELISA (enzyme-linked immunosorbent assay), "sandwich” immunoassays, immunoradiometric assays, gel diffusion precipitin reactions, immunodiffusion assays, in situ immunoassays (using colloidal gold, enzyme or radiois
  • antibody binding is detected by detecting a label on the primary antibody.
  • the primary antibody is detected by detecting binding of a secondary antibody or other reagent to the primary antibody.
  • the secondary antibody is labeled. Means are known in the art for detecting binding in an immunoassay and are within the scope of the present invention.
  • the foregoing antibodies can be used in methods known in the art relating to the detection or localization of influenza A viruses, e.g., Western blotting, ELISA, radioimmunoassay, immunofluorescence assay, immunohistochemical assay, and the like.
  • the techniques disclosed herein may be applied to the qualitative and quantitative determination of the HA2 peptide of influenza A viruses and to the diagnosis and surveillance of animals or humans infected with influenza A viruses.
  • the present invention also includes assay and test kits for the qualitative and/or quantitative determination of the HA2 peptide of influenza A viruses.
  • assay systems and test kits may comprise a labeled component prepared, e.g., by labeling with a radioactive atom, a fluorescent group or an enzyme, coupling a label to the mAb or related binding protein of the present invention, or to a binding partner thereof.
  • assay or test kits further may comprise reagents, diluents and instructions for use, as is well known to those skilled in immunoassay techniques.
  • kits will contain at least the mAb or related binding protein of the invention, means for detecting immunospecific binding of said mAb or related binding protein to AIV in a biological sample, and instructions for use, depending upon the method selected, e.g., "competitive,” “sandwich,” “DASP” and the like.
  • the kits may also contain positive and negative controls. They may be configured to be used with automated analyzers or automated immunohistochemical slide staining instruments.
  • An assay kit of the invention can further comprise a second antibody or binding protein that can be labeled or can be provided for attachment to a solid support (or attached to a solid support).
  • a second antibody or binding protein may be, for example, one that binds to influenza A viruses, particularly AIV.
  • Such second antibodies or binding proteins can be polyclonal or monoclonal antibodies.
  • Monoclonal antibodies to HA2 peptide of Influenza A hemagglutinin protein can be prepared by immunizing animals with Influenza A virus HA protein or fragments thereof.
  • a preferred method involves amplification of the H5N1 HAO and HA2 genes followed by expression of the gene, recovery and purification of H5N1 recombinant proteins and use of the purified proteins as immunogens.
  • H5N1 AIV is propagated by inoculation of chicken embryos with available strains of the virus, followed by isolation of the viral RNA.
  • the HA2 gene is amplified by reverse transcriptase polymerase chain reaction (RT-PCR) and then can be cloned into a baculovirus vector that is used to express H5N1 proteins in insect cells.
  • RT-PCR reverse transcriptase polymerase chain reaction
  • the proteins so produced then can be used to immunize mice or other suitable species for production of hybridomas.
  • immunological methods to detect influenza viruses include, for example, dot-blot and in situ hybridization formats.
  • influenza A virus mAb of this invention has advantages over other current methodologies as diagnostic tools.
  • the monoclonal antibody of the present invention can recognize all, or essentially all, influenza A viruses including the highly infectious H5 AIV. Additionally, this mAb provides a safe and convenient diagnostic approach for the detection of influenza A viruses including H5 AIV.
  • the antibody and related binding proteins of the invention can be administered to treat subjects suffering from an influenza A infection, for example, an infection from an avian influenza virus, such as an H5 subtype, and particularly an H5N1 subtype of AIV.
  • the antibody and related binding proteins of the invention also can be administered to subjects as a preventive measure in the event of an influenza pandemic or threatened pandemic.
  • the antibody and related binding proteins can be administered in a single dose or in repeated administrations, optionally in a slow release form. Administration can be made by any means that enables the antibody to reach its site of action in the body of the subject being treated, e.g., intravenously, intramuscularly, intradermally, orally or nasally.
  • the antibody is administered in a pharmaceutically acceptable diluent or carrier, such as a sterile aqueous solution, and the composition can further comprise one or more stabilizers, adjuvants, solubilizers, buffers, etc.
  • a pharmaceutically acceptable diluent or carrier such as a sterile aqueous solution
  • the composition can further comprise one or more stabilizers, adjuvants, solubilizers, buffers, etc.
  • the dosage of antibody administered is within the range of about 0.1 mg/kg to about 10 mg/kg body weight when the antibody is administered to treat patients suffering from influenza A infection.
  • the dosage is reduced by about half, i.e.
  • a single recombinant antibody or binding protein of the invention can be administered for therapeutic purposes or combined with one or more antibodies.
  • the antibody of the present invention can be combined with neutralizing antibodies against HA1 protein. If antibodies to one or more generations of neutralization escape mutants have been produced, such antibodies and the 1C9 antibody described above can be administered as therapeutic antibody cocktails
  • CHO-K1 cells and MDCK cells were obtained from American Type Culture Collection. They were cultured in Ham's F12-K medium and Dulbecco's Minimal Essential Medium respectively, both supplemented with 10% fetal bovine serum (FBS), 100 mg/ml streptomycin and 100 units penicillin, and maintained at 37 0 C, 5% CO 2.
  • FBS fetal bovine serum
  • streptomycin 100 mg/ml streptomycin and 100 units penicillin
  • the human HPAI H5N1 virus A/lndonesia/TLL013/06 was obtained from Ministry of Health (MOH), Indonesia.
  • the clade 1.0 virus, A ⁇ /ietnam/1203/2004 (H5N1) was rescued by reverse genetics. Briefly, the synthesized HA and NA genes were cloned into a dual- promoter plasmid for influenza A reverse genetics (16). Dual-promoter plasmids were obtained from the Center for Disease Control and Prevention, Atlanta, GA 1 USA.
  • the reassortant virus was rescued by transfecting plasmids containing HA and NA together with the remaining six gene plasmids derived from A/Puerto Rico/8/34 (H1 N1 ) into co-culture of 293T and MDCK cells using Lipofectamine 2000 (Invitrogen Corp). After 72 h of transfection, culture medium from the transfected cells was inoculated into 11 day-old embryonated chicken eggs or MDCK cells. The HA and NA genes of reassortant viruses were sequenced to confirm presence of introduced HA and NA genes. The viruses were propagated in the allantoic cavity of 11 day old chicken embryos and the allantoic fluid was harvested from the eggs after 48 h.
  • Virus titers were determined using hemagglutination assays (17). The virus was then clarified and stored at -80° C. All experiments with live viruses were performed in a biosafety level 3 containment laboratory and all the animal experiments were carried out in an Animal biosafety level 3 (ABSL3) containment laboratory in compliance with CDC/NIH and WHO recommendations (18, 19) and also were approved by the Agri-Food and Veterinary Agency (AVA) and MOH, Singapore.
  • ABSL3 Animal biosafety level 3
  • the total RNA was extracted from H5N1 (A/goose/Guangdong/97) by using Trizol (Invitrogen, USA).
  • the HAO gene and the HA2 gene were amplified from the cDNA and cloned into pQE-30 vector (Qiagen, Germany) using standard cloning techniques for expression in bacteria.
  • the clones were transformed into Escherichia coli M15 pREP4 competent cells to express the protein.
  • the transformed E.coli M15 cells were grown at 37° C to an OD 6 oo of 0.5 - 0.6 in Luria-Bertani (LB) medium containing ampicillin (100 ⁇ g/ml) and protein expression was induced by the addition of 1 mmol/L IPTG for 3 h with shaking.
  • the histidine tagged protein was purified on Ni-NTA column (Qiagen, Germany) using standard protocols.
  • mice were immunized two times subcutaneously at regular intervals of 2 weeks with 25 ⁇ g of recombinant H5N1 HAO antigen in 0.1 ml of Phosphate Buffered Saline (PBS), which was emulsified with an equal volume of adjuvant (SEPPIC, France). Thereafter, mice were boosted intravenously with 25 ⁇ g of recombinant antigen 3 days before the fusion of splenocytes with SP2/0 cells (20). The fused cells were seeded in 96-well plates, and their supematants were screened by immunofluorescence assays as described below. Positive clones were checked for isotype by using a one-minute isotyping kit (Amersham Bioscience, England) as described in the manufacturer's protocol.
  • PBS Phosphate Buffered Saline
  • SEPPIC adjuvant
  • the monoclonal antibody 1C9 which was positive by IFA and immunoblotting, was chosen for epitope mapping.
  • a total of 14 clones expressing fragments of HA2 with sequentially increasing number of amino acids were generated (Fig 1 ).
  • the cell lysates, after protein induction, from these clones were run on a SDS-PAGE and Immunoblotting analysis using the anti-HA2 mAbs showed mAb 1C9 was positive to the fragments number 1- 6 and negative to all the other fragments (Fig 1 b). With this, it was concluded that the mAb 1C9 recognized an epitope containing amino acids 331 to 345 of HAO (1-15 of HA2).
  • the HAO precursor of influenza A hemagglutinin was expressed on the surface of CHO-K1 cells. Upon treatment with trypsin and low pH, the HAO undergoes a conformational change from the native to the fusion active form resulting in polykaryon formation. Normal polykaryon formation was observed in the control well. The formation of polykaryon was completely inhibited by mAb 1 C9 at a concentration of 100 ⁇ g/ml and partially at a concentration of 50 ⁇ g/ml. An irrelevant monoclonal antibody 3H5 did not show any inhibition of polykaryon formation.
  • mice were used.
  • mice challenged with the H5N1 viruses PBS control group (untreated mice) showed the most rapid decline in bodyweight, culminating in 100% mortality within 5 days after viral challenge.
  • the body weight of succumbed mice from this group was below 80% of the original body weight (Fig. 4c).
  • the mice from the group treated one day after infection, with 10mg/kg of 1C9 mAb showed up to 15% loss of bodyweight and from 5 days after challenge the mice started gradually regaining their bodyweight (Fig. 4c).
  • mAb1 C9 completely protected mice from disease upon challenge with both the clades of H5N1 viruses (Fig 4b).
  • mice showed ⁇ 23% loss of bodyweight and from 4 days after challenge and gradually regained about 8-10% of the lost bodyweight (Fig 4c).
  • the groups of mice treated with 5mg/kg of 1C9 showed a loss of body weight less than 22%.
  • the mortality studies showed that this concentration provided 50% protection against 5 MLD 50 of two H5N1 strains, clade 1.0 (Fig. 4a) and clade 2.1 (Fig. 4b).
  • the groups of mice were treated with 1C9 mAb three days post challenge with the two H5N1 strains. Three days after the challenge (before treatment) 16.6-33.3 % (1-2 mice out of six/group) of the mice/group died and the therapeutic efficacy of the mAb was tested only in the surviving mice.
  • the 10 mg/kg of 1C9 mAb provided 75% (3 out of 4 mice survived) protection against H5N1 strains (Fig. 4d and Fig. 4e).
  • the 5 mg of 1C9 mAb provided 50% (2 out of 4 survived) protection against 5MLD 5 o H5N1 strains (Fig. 4d and Fig. 4e).
  • PBS 0 mg/kg
  • mice were challenged with 5MLD 50 of the two different H5N1 strains. Mice were observed daily to monitor body weight and mortality. Monitoring continued until all animals died or until day 14 after challenge.
  • mice pre-treated with 10 mg/kg of 1 C9 mAb provided 100% protection against 5 MLD 50 of two H5N1 strains, clade 1.0 (Fig. 5a) and clade 2.1 (Fig. 5b). This group of mice showed only 15% loss in body weight on day 5 and regained the body weight (Fig.5c).
  • Pre-treatment with 1C9 mAb at 5mg/kg provided 50% protection against 5MLD 50 H5N1 viruses from clade 1.0 (Fig. 5a) and clade 2.1 respectively (Fig. 5b).
  • RNA 400 ng/sample
  • AMV reverse transcriptase 20 U of AMV reverse transcriptase (Roche).
  • the cDNA suspension was used for amplification in a quantitative real-time PCR reaction.
  • DyNAmo TM Capillary SYBR Green qPCR kit (Finnzymes) was used in the PCR assay.
  • the cDNA was amplified in 20 ⁇ l containing, 0.25 ⁇ mol of forward primer (5'-GAAATCAAACAGATTAGTCCTTGC-S') (SEQ ID NO:1 ), and 0.25 ⁇ mol of reverse primer (5'-CCTGCCATCCTCCCTCTATAAA-S') (SEQ ID NO:2), and 1X of the DyNAmo master mix. Reactions were performed in a Light Cycler (Roche, Indiana, USA) with the following conditions: 10 min at 95° C, followed by 50 cycles of 95° C for 10 s, 57° C for 5 s, and 72° C for 9 s. Fluorescence signals from these reactions were captured at the end of the extension step in each cycle.
  • PCR products were subjected to melting curve analysis at the end of the assay (65 to 95° C; 0.1 ° C/s). Plasmids containing the target sequence were used as positive controls.
  • serial dilutions of plasmid DNA containing the target sequence were made and subjected to the real-time quantitative PCR assay. The assay was able to distinguish 10-fold differences in concentration over a range from 1000 to 10 9 copies, and no signal was observed in the water control. Relative quantification in triplicate for each experimental sample was obtained by using the standard curve method.
  • a real time polymerase chain reaction assay was used to evaluate the kinetics of the influenza A virus load in the lung samples of the animals infected with clade 2.1. Titers of viruses in the lungs of mice treated with mAb 1C9 24 hours pre-challenge were compared with those for the untreated mice (Fig. 6a). Titers of viruses in the lungs of mice treated with mAb 1C9 24 hours post- challenge were compared with those for the untreated mice (Fig. 6b). Mice receiving 10mg/kg of 1C9 showed significantly lesser viral load when compared to the untreated mice on day 4 and no virus titer was detected on day 10 post- challenge. Moreover, mice receiving 5 mg/kg of the same mAb showed lesser viral clearance when compared to the mice receiving 10 mg/kg of 1 C9 in a dose dependent manner.
  • mice infected with the clade 2.1 H5N1 virus had pulmonary lesions consisting of moderate to severe necrotizing bronchitis, moderate to severe histiocytic alveolitis with associated pulmonary edema (Fig 3b).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

This invention relates to methods and products for the diagnosis, surveillance, prevention, and treatment of influenza A virus infections in animals and humans. More particularly, the invention relates to antibodies and related binding proteins for the detection, prevention and treatment of influenza A viruses. The monoclonal antibodies and related binding proteins of the invention are useful for the treatment of the highly pathogenic H5 subtypes of avian influenza virus (AIV).

Description

Monoclonal Antibodies Specific to the Fusion Peptide from Hemagglutinin from Influenza A Viruses and Uses Thereof
FIELD OF THE INVENTION
This invention relates to methods and products for the diagnosis, surveillance, prevention, and treatment of influenza A virus infections in animals and humans. More particularly, the invention relates to antibodies and related binding proteins for the detection, prevention and treatment of influenza A viruses. The monoclonal antibodies and related binding proteins of the invention are useful for the treatment of the highly pathogenic H5 subtypes of avian influenza virus (AIV).
BACKGROUND OF THE INVENTION Highly Pathogenic avian Influenza (HPAI) H5 strains are currently causing major morbidity and mortality in poultry populations across Asia, Europe, and Africa and have caused 385 confirmed human infections, with a fatality rate of 63.11 % (1 , 2)1. Preventive and therapeutic measures against circulating H5N1 strains have received a lot of interest and effort globally to prevent another pandemic outbreak. Influenza A virus poses a challenge as it
A bibliography is provided at the end of the disclosure. rapidly alters its appearance to the immune system by antigenic drift (mutating) and antigenic shift (exchanging its components) (3). The current combat strategies against influenza include vaccination and anti-viral drug treatment, with vaccination being the preferred option. The annual influenza vaccine aims to stimulate the generation of anti-hemagglutinin neutralizing antibodies, which confer protection against homologous strains. The current vaccines have met with varying degrees of success (4). The fact that these strategies target the highly variable HA determinant and predicting the major HA types that pose the next epidemic threat, can impose limitations to the current viral strategy. In the absence of an effective vaccine, therapy is the mainstay of control of influenza infection. Therefore, therapeutic measures against influenza will play a major role in case a pandemic arises due to H5 strains. Currently licensed anti-viral drugs include the M2 ion channel inhibitors (Rimantidine and Amantidine) and the neuraminidase inhibitors (Oseltamivir and Zanamivir). The H5N1 viruses are known to be resistant to the M2 ion channel inhibitors (5, 6). Newer strains of H5N1 viruses are being isolated which are even resistant to the neuraminidase inhibitors (Oseltamivir and Zanamivir) (3, 7). The neuraminidase inhibitors also may need high doses and prolonged treatment (3, 8). Hence, alternative strategies for treatment of influenza are warranted. Recently, passive immunotherapy using monoclonal antibodies are being viewed upon as a viable treatment option (9).
Testing during an outbreak of an acute respiratory disease can determine if influenza is the cause. During influenza season, testing of selected patients presenting with respiratory illnesses compatible with influenza can help establish whether influenza is present in a specific patient population and help health-care providers determine how to use their clinical judgment for diagnosing and treating respiratory illness. A rapid influenza test helps in the determination of whether to use an antiviral medication. Some tests, such as a viral culture, reverse-transcriptase polymerase chain reaction (RT-PCR) and serological testing are the routine methods, but results may not be available in a timely manner to assist clinicians. At present, most of the rapid diagnostic tests currently in use are monoclonal antibody-based immunoassays. Immunofluorescence (fluorescent antibody staining) is the alternative to rapid influenza diagnostic tests which can be used in many hospital laboratories and generally can yield test results in 2-4 hours. Above all, specific monoclonal antibody generation is fundamental to most currently used rapid, sensitive and cost-effective diagnostic methods. Hemagglutinin (HA) is the most variable gene of the influenza virus and also the most promising target for generating antibodies. It is synthesized as a precursor polypeptide HAO, which is post-translationally cleaved to two polypeptides HA1 and HA2 linked by a disulphide bond. Monoclonal antibodies against the HA1 are known to neutralize the infectivity of the virus and hence provide good protection against infection (10). However, they are less efficient against heterologous or mutant strains which are continuously arising due to antigenic shift. Also, there is the risk of escape mutants being generated which could cause annual epidemics and occasional pandemics. The HA2 N-terminal fusion peptide is the most highly conserved region in HA among all influenza A subtypes (11). This HA2 polypeptide is responsible for the fusion of the virus and the host endosomal membrane during the entry of the virus into the cell (12). Part of the HA2 N-terminal fusion peptide is exposed as a surface loop in the precursor molecule (13, 14). As most HA subtypes are cleaved by extracellular enzymes, this surface loop is accessible to antibody on HAO expressed in the plasma membrane of infected host cells (15).
It would be very useful to have available monoclonal antibodies which broadly recognize and can treat influenza A viruses, especially H5 viruses.
OBJECTS OF THE INVENTION
An object of this invention is to provide monoclonal antibodies (mAbs) and related binding proteins that bind to influenza A virus, particularly to the HA2 polypeptide of influenza A viruses. The HA2 polypeptide is highly conserved in influenza A subtypes. Thus, mAbs that specifically recognize the HA2 polypeptide will recognize all influenza A subtypes. The specificity of these monoclonal antibodies provides a basis for effective prophylactic and therapeutic agents.
SUMMARY OF THE INVENTION
In accordance with the present invention, a monoclonal antibody that is specific for conformational epitopes of the influenza A hemagglutinin glycoprotein is provided. The HA2 polypeptide represents the highly conserved region of the hemagglutinin across influenza A strains. The monoclonal antibody binds specifically to the antigenically conserved fusion peptide of HA2 and is effective in providing cross-clade protection against influenza A infections.
MAbs that target conserved epitopes are useful for detecting the virus in tissues which have not been pre-treated, such as frozen tissue specimens and other biological tissues and fluids. In particular, a mAb designated 1C9 targets an epitope on HA2 of influenza A virus, for example, AIV subtypes. Accordingly, this invention comprises a binding protein having substantially the immunological binding characteristics for a conformational HA2 epitope as those of mAb 1 C9.
In a further aspect, the invention comprises a method for detecting influenza A virus in a specimen which comprises detecting the binding of the HA2 polypeptide with a mAb or binding protein having substantially the immunological binding characteristics of mAb 1C9. In particular, the invention relates to immunofluorescence assays, immunohistochemical assays and other methods that utilize such binding proteins.
In another aspect, the invention relates to kits for the detection of influenza A virus which comprise binding proteins having substantially the immunological binding characteristics of mAb 1C9.
The invention further relates to methods of treating subjects infected with influenza A virus strain, which comprise administering to such subjects effective amounts of one or more recombinant monoclonal antibodies or binding proteins or fragments thereof having substantially the immunological binding characteristics of mAb 1C9.
The invention further relates to methods of providing cross-clade protection against infection against the fusion peptide of the HA2 glycoprotein which comprise administering to such subjects effective amounts of one or more recombinant monoclonal antibodies or binding proteins or fragments thereof having substantially the immunological binding characteristics of mAb 1C9.
BRIEF DESCRIPTION OF THE DRAWINGS
Figures 1a-1c show the epitope mapping of monoclonal antibodies 1C9. Figure 1a represents gene-segments coding for fragments 1 to 14 of HA2. Western Blotting analyses of the monoclonal antibodies were performed to map their respective epitopes (the numbers indicate the amino acid number on HAO). Figure 1b. Western blot analysis of the 14 fragments: mAb1C9 was used as the primary antibody. Lane 1 had the protein molecular weight marker. Lanes 2 and 18 show recombinant HA2 gp, Lane 3 shows HA2 from whole virus, Lanes 4 to 17 show the 14 fragments. Only fragments 1 to 6 show positive results, while fragments 7 to 14 show negative results. The samples were run on three different gels but processed identically.
Figure 1c. The results of Western blot analysis of point mutants also expressed as histidine-fusion peptides. The membrane was developed using ECL reagents. The analysis was carried out to determine the amino acid sequence of the epitope for mAb 1C9. Lanes 1 and 16 had the protein molecular weight marker. Lanes 2 and 17 show the wild-type fragment 1. Lanes 3 to 15, 18 and 19 were loaded with the over expressed point mutants. Positive results were seen only in lanes with wild type fragment 1 , point mutants I340A (12), E341A (13), G342A (14), G343A (15), W344A (18) and Q345A (19), indicating the absence of the role of the respective amino acids in binding to the HA2 gp. Negative results were seen in lanes with point mutants G331A (3), L332A (4), F333A (5), G334A (6), A335A (7), I336A (8), A337G (9), G338A (10) and F339A (11 ), indicating the role of these amino acids in forming the epitope of mAb 1 C9. Lane numbers of the respective point mutants are indicated in brackets. The samples were run on two different gels but processed identically. Figure 2. Inhibition of cell to cell fusion of CHO cells expressing the HAO precursor, (a) Cells without trypsin treatment, following pH5 treatment, (b) cells after trypsin treatment and following pH5 treatment, (c) cells after trypsin treatment and following pH5 treatment in the presence of 10μg/ml of mAb 1C9, (d) in the presence of 50 μg/ml of mAb 1C9, (e) in the presence of 100 μg/ml of mAb 1C9, (f) in the presence of 100 μg/ml of non-specific mAb 3H5. Figure 3. Photomicrographs of hematoxylin- and eosin- stained lung sections of mice infected with Clade 2.1 H5N1 virus at 5 days post challenge, a) Normal morphology seen in uninfected mice, b) infected and untreated mice, c) infected mice treated with 5mg/kg of 1C9 at 24 hour post challenge, d) infected mice treated with 10 mg/kg of 1C9 at 24 hour post challenge, e) infected mice treated with 5 mg/kg of 1C9, 24 hours prior to viral challenge, f) infected mice treated with 10 mg/kg of 1C9, 24 hours prior to viral challenge.
Figure 4a. Protection of mice from lethal H5N1 viral challenge. Each group of mice was intra-peritoneally treated with 10 mg/kg, 5 mg/kg or 0 mg/kg (PBS) of 1C9 mAb after 1 day post viral challenge with mouse-adapted Indonesian HPAI H5N1 (A/Vietnam/1203/04-Clade 1.0) virus. Mice were monitored for survival throughout a 14 day observation period. The results are expressed in terms of percent survival. Figures 4b and 4c. Protection of mice from lethal H5N1 viral challenge. Each group of mice was intra-peritoneally treated with 10 mg/kg, 5 mg/kg or 0 mg/kg (PBS) of 1C9 mAb after 1 day post viral challenge with mouse-adapted Indonesian HPAI H5N1 (A/TLL013/06-Clade 2.1 ) virus. Mice were monitored for survival (Fig. 4b) and weight loss (Fig. 4c) throughout a 14 day observation period. The results are expressed in terms of percent survival and percent body weight (at the beginning of the trial), respectively (* represents no survival of any animals in the group).
Figure 4d. Protection of mice from lethal H5N1 viral challenge. Each group of mice were intra-peritoneally treated with 10 mg/kg, 5 mg/kg or 0 mg/kg (PBS) of 1C9 mAb after 3 day post viral challenge with mouse-adapted Indonesian HPAI H5N1 (A/Vietnam/1203/04-Clade 1.0) virus. Mice were monitored for survival throughout a 14 day observation period. The results are expressed in terms of percent survival. Figures 4e and 4f. Protection of mice from lethal H5N1 viral challenge. Each group of mice was intraperitoneal^ treated with 10 mg/kg, 5 mg/kg or 0 mg/kg (PBS) of 1C9 mAb after 3 day post viral challenge with mouse-adapted Indonesian HPAI H5N1 (A/TLL013/06-Clade 2.1 ) virus. Mice were monitored for survival (Fig. 4e) and weight loss (Fig. 4f) throughout a 14 day observation period. The results are expressed in terms of percent survival and percent body weight (at the beginning of the trial), respectively (* represents no survival of any animals in the group). Figure 5a. Protection of mice from lethal H5N1 viral challenge. Each group of mice were intra-peritoneally pre-treated with 10 mg/kg, 5 mg/kg or 0 mg/kg (PBS) of 1C9 mAb on 1 day before challenge with mouse-adapted Indonesian HPAI H5N1 (A/Vietnam/1203/04-Clade 1.0) virus. Mice were monitored for survival throughout a 14 day observation period. The results are expressed in terms of percent survival. Figures 5b and 5c. Protection of mice from lethal H5N1 viral challenge. Each group of mice were pre-treated with 10 mg/kg, 5 mg/kg or 0 mg/kg (PBS) of 1C9 mAb on 1 day before challenge with mouse-adapted Indonesian HPAI H5N1 (A/TLL013/06-Clade 2.1 ) virus. Mice were monitored for survival (Fig. 5b) and weight loss (Fig. 5c) throughout a 14 day observation period. The results are expressed in terms of percent survival and percent body weight (at the beginning of the trial), respectively (* represents no survival of any animals in the group). Figure 6a . shows the measurement of viral loads by qPCR , in the lungs of pre-treated mice and mice challenged with virus. Each group of mice was pre- treated with 10 mg/kg, 5 mg/kg or 0 mg/kg (PBS) of 1C9 mAb on 1 day before challenge with mouse-adapted Indonesian HPAI H5N1 (A/TLL013/06-Clade 2.1) virus. The viral loads were measured in the lungs of the infected animals on days 2, 4 and 10 post challenge. The results are expressed in terms of mean value of log (number of copies)/400ng of RNA ± S. D. (# represents no survival of any animals in the group and & represents undetectable viral numbers; *** p<0.01). Figure 6b. shows the measurement of viral loads by qPCR , in the lungs of infected animals challenged with virus and subsequently treated. Each group of mice was challenged with mouse-adapted Indonesian HPAI H5N1 (A/TLL013/06-Clade 2.1 ) virus and treated with 10 mg/kg, 5 mg/kg or 0 mg/kg (PBS) of 1C9 mAb 1 day after challenge. The viral loads were measured in the lungs of the infected animals on days 2, 4 and 10 post challenge. The results are expressed in terms of mean value of log (number of copies)/400ng of RNA ± S. D. (# represents no survival of any animals in the group and & represents undetectable viral numbers; *** p<0.01 ).
DETAILED DESCRIPTION OF THE INVENTION
The present invention is directed to mAbs and related antigen-binding proteins that bind specifically to the HA2 N-terminal fusion peptide of influenza A virus. In particular, the mAb or related antigen binding protein possesses the immunological binding characteristics of mAb 1C9, as produced by hybridoma 1C9, deposited with the American Type Culture Collection (ATCC), VA, USA, under the terms of the Budapest Treaty on November 6, 2007, and assigned Accession Number PTA-8759. The invention further embodies this hybridoma which provides a continuous source of the mAbs and binding proteins of the invention. The invention further relates to methods for the detection and diagnosis of influenza A infection and assay kits that comprise the mAbs or binding proteins of the invention.
The invention further relates to methods of treating a subject infected with an influenza A virus through the administration of effective amounts of an antibody fragment or recombinant antibody comprising an antibody or related binding protein of the invention. In one embodiment the subject is infected with an H5 AIV. The antibody of this invention also can be administered to subjects on the advent of a possible influenza pandemic as a precautionary measure. In this instance, effective amounts of antibody to be administered are about half of the amounts used to treat influenza A virus infections.
Various terms are used herein, which have the following meanings: The term "immunological binding characteristics" of a mAb or related binding protein, in all of its grammatical forms, refers to the specificity, affinity and cross-reactivity of the mAb or binding protein for its antigen.
The term "binding protein@ refers to a protein, including those described below, that includes the antigen binding site of a mAb of the present invention or a mAb having the immunological binding characteristics of a mAb of the present invention.
The present invention advantageously provides methods for preparing monoclonal antibodies having the binding characteristics of mAb 1C9 by immunizing an animal with an H5N1 virus (A/goose/Guangdong/97). Any such antigen can be used as an immunogen to generate antibodies with the desired immunological binding characteristics. Such antibodies include, but are not limited to, monoclonal antibodies, chimeric antibodies, single chain antibodies, Fab fragments and proteins comprising the antigen binding sequence of mAb 1 C9.
The mAb of the present invention can be produced by any technique that provides for the production of antibody molecules by continuous cell lines in culture. Such methods include, but are not limited to, the hybridoma technique originally developed in 1975 by Kohler and Milstein (Nature 256:495-497), as well as the trioma technique, the human B-cell hybridoma technique (Kozbor et al., 1983, Immunology Today 4:72) and the EBV-hybridoma technique to produce human monoclonal antibodies (Cole et al., in Monoclonal Antibodies and Cancer Therapy Alan R. Liss, Inc., pp 77-96 (1985)). Human antibodies can be used and can be obtained by using human hybridomas (Cote et al., 1983, Proc. Nat=l. Acad. Sci. U.S.A., 80:2026-2030) or by transforming human B cells with EBV virus in vitro (Cole et al., 1985, in Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, pp. 77-96). Moreover, techniques developed for the production of "chimeric antibodies" or "humanized antibodies" (Morrison et al., 1984, J. Bacteriol. 159-870; Neuberger et al., 1984, Nature 372:604-608; Takeda et al., 1985, Nature 374:452-454) by introducing sequences from a murine antibody molecule of the present invention, e.g., mAb 1C9, together with genes from a human antibody molecule of appropriate biological activity can be used. Chimeric antibodies are those that contain a human Fc portion and a murine (or other non-human) Fv portion. Humanized antibodies are those in which the murine (or other non-human) complementarity determining regions (CDR) are incorporated into a human antibody. Both chimeric and humanized antibodies are monoclonal. Such human or humanized chimeric antibodies are preferred for use in in vivo diagnosis or therapy of human diseases or disorders.
According to the invention, techniques described for the production of single chain antibodies (U.S. Patent 4,946,778) can be adapted to provide single chain antibodies of the present invention. An additional embodiment of the invention utilizes the techniques described for the construction of Fab expression libraries (Huse et al., 1989, Science 246: 1275-1281 ) to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity for an antibody of the present invention, or its derivatives, or analogs. Antibody fragments that contain the idiotype of the antibody molecule can be generated by known techniques. For example, such fragments include but are not limited to: the F(ab=)2 fragment which can be produced by pepsin digestion of the antibody molecule; the Fab= fragments which can be generated by reducing the disulfide bridges of the F(ab=)2 fragment, and the Fab fragments which can be generated by treating the antibody molecule with papain and a reducing agent. Such antibody fragments can be generated from any of the polyclonal or monoclonal antibodies of the invention. In the production of antibodies, screening for the desired antibody can be accomplished by techniques known in the art, e.g., radioimmunoassay, ELISA (enzyme-linked immunosorbent assay), "sandwich" immunoassays, immunoradiometric assays, gel diffusion precipitin reactions, immunodiffusion assays, in situ immunoassays (using colloidal gold, enzyme or radioisotope labels, for example), western blots, precipitation reactions, agglutination assays (e.g., gel agglutination assays, hemagglutination assays), immunofluorescence assays and Immunoelectrophoresis assays, etc. In one embodiment, antibody binding is detected by detecting a label on the primary antibody. In another embodiment, the primary antibody is detected by detecting binding of a secondary antibody or other reagent to the primary antibody. In a further embodiment, the secondary antibody is labeled. Means are known in the art for detecting binding in an immunoassay and are within the scope of the present invention.
The foregoing antibodies can be used in methods known in the art relating to the detection or localization of influenza A viruses, e.g., Western blotting, ELISA, radioimmunoassay, immunofluorescence assay, immunohistochemical assay, and the like. The techniques disclosed herein may be applied to the qualitative and quantitative determination of the HA2 peptide of influenza A viruses and to the diagnosis and surveillance of animals or humans infected with influenza A viruses.
The present invention also includes assay and test kits for the qualitative and/or quantitative determination of the HA2 peptide of influenza A viruses. Such assay systems and test kits may comprise a labeled component prepared, e.g., by labeling with a radioactive atom, a fluorescent group or an enzyme, coupling a label to the mAb or related binding protein of the present invention, or to a binding partner thereof. Such assay or test kits further may comprise reagents, diluents and instructions for use, as is well known to those skilled in immunoassay techniques.
In certain embodiments of the invention, such kits will contain at least the mAb or related binding protein of the invention, means for detecting immunospecific binding of said mAb or related binding protein to AIV in a biological sample, and instructions for use, depending upon the method selected, e.g., "competitive," "sandwich," "DASP" and the like. The kits may also contain positive and negative controls. They may be configured to be used with automated analyzers or automated immunohistochemical slide staining instruments.
An assay kit of the invention can further comprise a second antibody or binding protein that can be labeled or can be provided for attachment to a solid support (or attached to a solid support). Such an antibody or binding protein may be, for example, one that binds to influenza A viruses, particularly AIV. Such second antibodies or binding proteins can be polyclonal or monoclonal antibodies.
Monoclonal antibodies to HA2 peptide of Influenza A hemagglutinin protein can be prepared by immunizing animals with Influenza A virus HA protein or fragments thereof. A preferred method involves amplification of the H5N1 HAO and HA2 genes followed by expression of the gene, recovery and purification of H5N1 recombinant proteins and use of the purified proteins as immunogens. For example, H5N1 AIV is propagated by inoculation of chicken embryos with available strains of the virus, followed by isolation of the viral RNA. The HA2 gene is amplified by reverse transcriptase polymerase chain reaction (RT-PCR) and then can be cloned into a baculovirus vector that is used to express H5N1 proteins in insect cells. The proteins so produced then can be used to immunize mice or other suitable species for production of hybridomas.
Other immunological methods to detect influenza viruses include, for example, dot-blot and in situ hybridization formats.
The influenza A virus mAb of this invention has advantages over other current methodologies as diagnostic tools. The monoclonal antibody of the present invention can recognize all, or essentially all, influenza A viruses including the highly infectious H5 AIV. Additionally, this mAb provides a safe and convenient diagnostic approach for the detection of influenza A viruses including H5 AIV.
In a further embodiment of the invention, the antibody and related binding proteins of the invention can be administered to treat subjects suffering from an influenza A infection, for example, an infection from an avian influenza virus, such as an H5 subtype, and particularly an H5N1 subtype of AIV. The antibody and related binding proteins of the invention also can be administered to subjects as a preventive measure in the event of an influenza pandemic or threatened pandemic. The antibody and related binding proteins can be administered in a single dose or in repeated administrations, optionally in a slow release form. Administration can be made by any means that enables the antibody to reach its site of action in the body of the subject being treated, e.g., intravenously, intramuscularly, intradermally, orally or nasally. Typically, the antibody is administered in a pharmaceutically acceptable diluent or carrier, such as a sterile aqueous solution, and the composition can further comprise one or more stabilizers, adjuvants, solubilizers, buffers, etc. The exact method of administration, composition and particular dosage will be determined and adjusted at the time of therapy, depending upon the individual needs of the subject, taking into account such factors as the subject=s age, weight, general health, and the nature and extent of his or her symptoms, as well as the frequency of treatment to be given. Generally, the dosage of antibody administered is within the range of about 0.1 mg/kg to about 10 mg/kg body weight when the antibody is administered to treat patients suffering from influenza A infection. Typically, the dosage is reduced by about half, i.e. to within the range of about 0.05 mg/kg to about 5 mg/kg body weight, when administered as a preventive measure. A single recombinant antibody or binding protein of the invention can be administered for therapeutic purposes or combined with one or more antibodies. Specifically, the antibody of the present invention can be combined with neutralizing antibodies against HA1 protein. If antibodies to one or more generations of neutralization escape mutants have been produced, such antibodies and the 1C9 antibody described above can be administered as therapeutic antibody cocktails
The following examples are provided to illustrate a preferred mode of practicing the invention. The invention is not limited to the details of the examples, but is commensurate with the full scope of the appended claims. Example 1 Production of Hybridomas
CHO-K1 cells and MDCK cells were obtained from American Type Culture Collection. They were cultured in Ham's F12-K medium and Dulbecco's Minimal Essential Medium respectively, both supplemented with 10% fetal bovine serum (FBS), 100 mg/ml streptomycin and 100 units penicillin, and maintained at 37 0C, 5% CO2. Avian influenza virus H5N1
(A/goose/Guangdong/97) was inactivated with betapropiolactone and used for RNA extraction to amplify the HAO gene. The human HPAI H5N1 virus A/lndonesia/TLL013/06 was obtained from Ministry of Health (MOH), Indonesia. The clade 1.0 virus, AΛ/ietnam/1203/2004 (H5N1) was rescued by reverse genetics. Briefly, the synthesized HA and NA genes were cloned into a dual- promoter plasmid for influenza A reverse genetics (16). Dual-promoter plasmids were obtained from the Center for Disease Control and Prevention, Atlanta, GA1 USA. The reassortant virus was rescued by transfecting plasmids containing HA and NA together with the remaining six gene plasmids derived from A/Puerto Rico/8/34 (H1 N1 ) into co-culture of 293T and MDCK cells using Lipofectamine 2000 (Invitrogen Corp). After 72 h of transfection, culture medium from the transfected cells was inoculated into 11 day-old embryonated chicken eggs or MDCK cells. The HA and NA genes of reassortant viruses were sequenced to confirm presence of introduced HA and NA genes. The viruses were propagated in the allantoic cavity of 11 day old chicken embryos and the allantoic fluid was harvested from the eggs after 48 h. Virus titers were determined using hemagglutination assays (17). The virus was then clarified and stored at -80° C. All experiments with live viruses were performed in a biosafety level 3 containment laboratory and all the animal experiments were carried out in an Animal biosafety level 3 (ABSL3) containment laboratory in compliance with CDC/NIH and WHO recommendations (18, 19) and also were approved by the Agri-Food and Veterinary Agency (AVA) and MOH, Singapore.
The total RNA was extracted from H5N1 (A/goose/Guangdong/97) by using Trizol (Invitrogen, USA). The HAO gene and the HA2 gene were amplified from the cDNA and cloned into pQE-30 vector (Qiagen, Germany) using standard cloning techniques for expression in bacteria. The clones were transformed into Escherichia coli M15 pREP4 competent cells to express the protein. The transformed E.coli M15 cells were grown at 37° C to an OD6oo of 0.5 - 0.6 in Luria-Bertani (LB) medium containing ampicillin (100 μg/ml) and protein expression was induced by the addition of 1 mmol/L IPTG for 3 h with shaking. The histidine tagged protein was purified on Ni-NTA column (Qiagen, Germany) using standard protocols.
BALB/c mice were immunized two times subcutaneously at regular intervals of 2 weeks with 25 μg of recombinant H5N1 HAO antigen in 0.1 ml of Phosphate Buffered Saline (PBS), which was emulsified with an equal volume of adjuvant (SEPPIC, France). Thereafter, mice were boosted intravenously with 25 μg of recombinant antigen 3 days before the fusion of splenocytes with SP2/0 cells (20). The fused cells were seeded in 96-well plates, and their supematants were screened by immunofluorescence assays as described below. Positive clones were checked for isotype by using a one-minute isotyping kit (Amersham Bioscience, England) as described in the manufacturer's protocol.
Example 2
Screening of mAbs by IFA
Sf-9 and MDCK cells in 96-well plates were infected with recombinant baculovirus harboring the truncated H5N1 HA1 and HAO gene, or with AIV
H5N1 Indonesian strains, H5N2 and H5N3 strains, respectively. At 36 h (for Sf-
9 cells) and 24-48 h (for MDCK cells) post-infection, the cells were fixed with
4% para-formaldehyde for 30 min at room temperature and washed thrice with PBS, pH 7.4. The fixed cells were incubated with hybridoma culture fluid at 37° C for 1 h. Cells were rinsed thrice with PBS and incubated with a 1 :40 dilution of fluorescein isothiocyanate (FITC)-conjugated rabbit anti-mouse Ig (Dako, Denmark). Cells were rinsed again in PBS, prior to scoring results in an epifluorescence microscope (Olympus, Japan) with appropriate barrier and excitation filters for optimized FITC visualization (21 ).
The monoclonal antibody 1C9, which was positive by IFA and immunoblotting, was chosen for epitope mapping. A total of 14 clones expressing fragments of HA2 with sequentially increasing number of amino acids were generated (Fig 1 ). The cell lysates, after protein induction, from these clones were run on a SDS-PAGE and Immunoblotting analysis using the anti-HA2 mAbs showed mAb 1C9 was positive to the fragments number 1- 6 and negative to all the other fragments (Fig 1 b). With this, it was concluded that the mAb 1C9 recognized an epitope containing amino acids 331 to 345 of HAO (1-15 of HA2). To further map the epitope of mAb 1C9 , several point mutants were generated which altered each of the amino acids in the approximately mapped epitope region, viz. amino acids 331-345 for mAb1C9. Further expression of the point mutants and immunoblotting analyses were carried out. The results showed positive results with mutants I340A, E341A, G342A, G343A, W344A and Q345A. The mutants G331A, L332A, F333A, G334A, A335G, I336A, A337G, G338A and F339A showed negative results on the western blot (Fig 1c). These data indicate that the mutants of the amino acids which showed negative results are the ones which are involved in the epitope and hence upon being mutated, were not recognized by the mAb 1C9. The other mutants were recognized by the mAb in spite of the point mutations. These data indicate that mAb 1C9 recognizes an epitope comprising the amino acids 'GLFGAIAGF' (331-339). The mAb 1C9 was against the HA1/HA2 joining region, specifically, against a part of the fusion peptide. Example 3 Screening effect of mAbs on HAO conformational change
The HAO precursor of influenza A hemagglutinin was expressed on the surface of CHO-K1 cells. Upon treatment with trypsin and low pH, the HAO undergoes a conformational change from the native to the fusion active form resulting in polykaryon formation. Normal polykaryon formation was observed in the control well. The formation of polykaryon was completely inhibited by mAb 1 C9 at a concentration of 100 μg/ml and partially at a concentration of 50 μg/ml. An irrelevant monoclonal antibody 3H5 did not show any inhibition of polykaryon formation.
Example 4
Therapeutic efficacy of the anti-HA2 mAb against H5N1 infection
To determine the therapeutic efficacy of mAb 1C9, inbred SPF BALB/c mice aged 4-6 weeks were used. Six mice (n=6) per group were anesthetized with Ketamine / Xylazine and intra-nasally infected with 5MLD50 (Mouse lethal dose 50%) of two different H5N1 strains (A/Vietnam/1203/2004 from cladei and
A/lndonesia/TLL013/06 from clade 2.1). Fifty percent mouse lethal dose (MLD50) was determined as previously described by Reed and Muench method (Reed and Muench, 1938). Each group of mice was treated via intra-peritoneal route with 5 mg/kg, 10 mg/kg or 0 mg/kg (PBS) of each anti- HA2 mAb at time points of 1 or 3 days after viral challenge Groups of experimental mice (n=6/group) were treated with indicated dosages of mAb, one or three days post challenge with 5 MLD50 of HPAI H5N1 strains from clade 1.0 or clade 2.1. The progress of infection was indicated by varying trends of decrease in body weight in the different groups. In mice challenged with the H5N1 viruses, PBS control group (untreated mice) showed the most rapid decline in bodyweight, culminating in 100% mortality within 5 days after viral challenge. The body weight of succumbed mice from this group, on day 3, was below 80% of the original body weight (Fig. 4c). The mice from the group treated one day after infection, with 10mg/kg of 1C9 mAb showed up to 15% loss of bodyweight and from 5 days after challenge the mice started gradually regaining their bodyweight (Fig. 4c). At high concentrations, mAb1 C9 completely protected mice from disease upon challenge with both the clades of H5N1 viruses (Fig 4b). The mice showed ~23% loss of bodyweight and from 4 days after challenge and gradually regained about 8-10% of the lost bodyweight (Fig 4c). The groups of mice treated with 5mg/kg of 1C9 showed a loss of body weight less than 22%. The mortality studies showed that this concentration provided 50% protection against 5 MLD50 of two H5N1 strains, clade 1.0 (Fig. 4a) and clade 2.1 (Fig. 4b). The groups of mice were treated with 1C9 mAb three days post challenge with the two H5N1 strains. Three days after the challenge (before treatment) 16.6-33.3 % (1-2 mice out of six/group) of the mice/group died and the therapeutic efficacy of the mAb was tested only in the surviving mice. The 10 mg/kg of 1C9 mAb provided 75% (3 out of 4 mice survived) protection against H5N1 strains (Fig. 4d and Fig. 4e). The 5 mg of 1C9 mAb provided 50% (2 out of 4 survived) protection against 5MLD5o H5N1 strains (Fig. 4d and Fig. 4e).
Example 5
Prophylactic efficacy of anti-HA2 mAb against H5 infection
To determine the prophylactic efficacy, a group of mice (n=6/group) was pre-treated with 5mg/kg, 10mg/kg or 0 mg/kg (PBS) of mAb 1C9, prior to the viral challenge. After 24 h, mice were challenged with 5MLD50 of the two different H5N1 strains. Mice were observed daily to monitor body weight and mortality. Monitoring continued until all animals died or until day 14 after challenge.
The group of mice pre-treated with 10 mg/kg of 1 C9 mAb provided 100% protection against 5 MLD50 of two H5N1 strains, clade 1.0 (Fig. 5a) and clade 2.1 (Fig. 5b). This group of mice showed only 15% loss in body weight on day 5 and regained the body weight (Fig.5c). Pre-treatment with 1C9 mAb at 5mg/kg provided 50% protection against 5MLD50 H5N1 viruses from clade 1.0 (Fig. 5a) and clade 2.1 respectively (Fig. 5b). Example 6
Determination of viral load
About 200 μl of the lung homogenates were treated with 1 ml Trizol reagent to extract RNA. Total RNA (400 ng/sample) were used for cDNA synthesis using 20 U of AMV reverse transcriptase (Roche). The cDNA suspension was used for amplification in a quantitative real-time PCR reaction. DyNAmo ™ Capillary SYBR Green qPCR kit (Finnzymes) was used in the PCR assay. Briefly, the cDNA was amplified in 20 μl containing, 0.25 μmol of forward primer (5'-GAAATCAAACAGATTAGTCCTTGC-S') (SEQ ID NO:1 ), and 0.25 μmol of reverse primer (5'-CCTGCCATCCTCCCTCTATAAA-S') (SEQ ID NO:2), and 1X of the DyNAmo master mix. Reactions were performed in a Light Cycler (Roche, Indiana, USA) with the following conditions: 10 min at 95° C, followed by 50 cycles of 95° C for 10 s, 57° C for 5 s, and 72° C for 9 s. Fluorescence signals from these reactions were captured at the end of the extension step in each cycle. To determine the specificity of the assay, PCR products were subjected to melting curve analysis at the end of the assay (65 to 95° C; 0.1 ° C/s). Plasmids containing the target sequence were used as positive controls. To determine the dynamic range of real-time quantitative PCR, serial dilutions of plasmid DNA containing the target sequence were made and subjected to the real-time quantitative PCR assay. The assay was able to distinguish 10-fold differences in concentration over a range from 1000 to 109 copies, and no signal was observed in the water control. Relative quantification in triplicate for each experimental sample was obtained by using the standard curve method.
A real time polymerase chain reaction assay was used to evaluate the kinetics of the influenza A virus load in the lung samples of the animals infected with clade 2.1. Titers of viruses in the lungs of mice treated with mAb 1C9 24 hours pre-challenge were compared with those for the untreated mice (Fig. 6a). Titers of viruses in the lungs of mice treated with mAb 1C9 24 hours post- challenge were compared with those for the untreated mice (Fig. 6b). Mice receiving 10mg/kg of 1C9 showed significantly lesser viral load when compared to the untreated mice on day 4 and no virus titer was detected on day 10 post- challenge. Moreover, mice receiving 5 mg/kg of the same mAb showed lesser viral clearance when compared to the mice receiving 10 mg/kg of 1 C9 in a dose dependent manner.
Example 7
Histopathology
For histopathology, a lung sample was collected in 10% (wt/vol) buffered formalin solution, embedded in paraffin and sectioned. Sections were stained with hematoxylin and eosin (H/E) and were analyzed for pathology. Histopathology studies were followed for mice treated with mAb 1C9 24h pre or post viral challenge. On day 5 p.i., mice infected with the clade 2.1 H5N1 virus had pulmonary lesions consisting of moderate to severe necrotizing bronchitis, moderate to severe histiocytic alveolitis with associated pulmonary edema (Fig 3b). The uninfected mice lacked lesions in the lungs (Fig 3a), mice treated (24h pre or post challenge) with 5 mg/kg of 1C9 had minimal to moderate bronchitis (Fig 3c and 3e) and mice treated (24h pre or post challenge) with 10 mg/kg of 1C9 had minimal bronchitis.
REFERENCES
1. WHO (World Health Organization). Cumulative Number of Confirmed Human Cases of Avian Influenza A/ (H5N1 ) Reported to WHO 10 September 2007. Available at: http://www.who.int/csr/disease/avian_influenza/country/cases_table_2008_01_0 3 /en/index.html. Accessed 03 January 2008.
2. No authors listed. 2006. Epidemiology of WHO confirmed human cases of avian influenza A (H5N1 ) infection .WkIy Epidemiol. Rec. 81 : 249-257.
3. de Jong, M.D, and T.T. Hien. 2006. Avian influenza A (H5N1)-Review. J. Clin. Virol. 35: 2-13.
4. Veits.J., A. Romer-Oberdorfer, D. Helferich., M. Durban. M. and et al. 2008. Protective efficacy of several vaccines against highly pathogenic H5N1 avian influenza virus under experimental conditions. Vaccine 26:1688-1696.
5. Beigel, J.H., J. Farrar, A.M. Han, F.G. Hayden, R. Hyer, M.D. de Jong, and et al. 2005. Avian influenza A (H5N1) infection in humans. N. Engl. J. Med.
353:1374-85.
6. Bright, R.A., D.K. Shay, B.Shu, NJ. Cox, and A.I. Klimov. 2006. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 295: 891-894. 7. Le, Q.M., M.Kiso, K.Someya, Y.T. Sakai, T.H. Nguyen, and et al. 2005. Avian flu : Isolation of drug-resistant H5N1 virus. Nature 437: 1108. 8. Yen, H.L., A.S. Monto, R.G. Webster, an E.A. Govorkova. 2005. Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic AΛ/ietnam/1203/04 influenza virus in mice. J. Infect. Dis. 192: 665-672.
9. Sawyer.L.A. 2000. Antibodies for the prevention and treatment of viral diseases. Antiviral. Res. 47: 57-77 10. Hanson, J.H., CM. Boon, P.C. Lim, A. Webb, E.E. Ooi, and RJ. Webb. 2006. Passive immunoprophylaxis and therapy with humanized monoclonal antibody specific for influenza A H5 hemagglutinin in mice. Respir. Res. 7:126 11. Gerhard, W., K. Mozdzanowska, and D. Zharikova 2006. Prospects for Universal Influenza Virus Vaccine. Emerging Infect. Dis. 12: 569-574. 12. Lakadamyali, M., M.J. Rust, and X. Zhuang. 2004. Endocytosis of influenza viruses. Microbes Infect. 6: 929-936.
13. Chen, J., K.H. Lee, D.A. Steinhauer, D.J. Stevens, J.J. Skehel, and D.. Wiley. 1998. Structure of the hemagglutinin precursor cleavage site, a determinant of influenza pathogenicity and the origin of the labile conformation. Cell 95:409-417.
14. Wilson, I.A., J.J. Skehel, and D.C. Wiley. 1981. Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution. Nature 289: 366-373.
15. Atassi, M.Z., and R.G. Webster. 1983. Location, synthesis and activity of an antigenic site on influenza virus hemagglutinin. PNAS 180: 840-844.
16. Horimota, T., A. Takada, K. Fujii, H. Goto, M. Hatta, and et al. 2006. The development and characterization of H5 influenza virus vaccines derived from a 2003 human isolate. Vaccine 24: 3669-3676. 17. Anonymous. 1995. Laboratory biosafety manual. World Health Organization. Ann 1st Super Sanita, 31, 1-121.
18. NIH (National Institutes of Health, U.S.) and CDCP (Centers for Disease Control and Prevention, U.S.) 1999. Biosafety in microbiological and biomedical laboratories, 4th ed. U.S. Dept. of Health and Human Services Public Health Service Centers for Disease Control and Prevention ; National Institutes of Health ;For sale by the Supt. of Docs. U.S. G. P.O., Washington, D.C.
19. WHO (World Health Organization). 2004. Laboratory biosafety manual, 3rd ed. World Health Organization, Geneva. 20. Yokoyama, W.M. 2001. Production of monoclonal antibody, p.2.5.1-2.5.17.
In J. E. Coligan, A.M. Kruisbeek, D. H. Margulies, E. M. Shevach, and W. Strober
(eds.), Current Protocols in Immunology, John Wiley & Sons.lnc, Newcastle,
United Kingdom.
21. Velumani, S., Q. Du, B.J. Fenner, M. Prabakaran, and et al. 2008. Development of an antigen-capture ELISA for detection of H7 subtype avian influenza from experimentally infected chickens. J. Virol. Methods 147: 219-225.

Claims

1. A binding protein that binds specifically to an epitope of a glycoprotein of influenza A virus that has substantially the immunological binding characteristics of monoclonal antibody 1C9.
2. The binding protein of claim 1 which is a monoclonal antibody, a single chain antibody, an antibody fragment, a chimeric antibody or a humanized antibody.
3. The binding protein of claim 1 which is a monoclonal antibody.
4. Monoclonal antibody 1C9 as produced by hybridoma 1C9 which is deposited with the American Type Culture Collection with Accession
Number PTA-8759.
5. A method for detecting an influenza A virus in a biological specimen which comprises contacting the specimen with a first binding protein that binds specifically to an epitope of a glycoprotein of influenza A virus, said first binding protein having substantially the immunological binding characteristics of monoclonal antibody 1C9.
6. The method of claim 5 wherein the first binding protein is a monoclonal antibody, a single chain antibody, an antibody fragment, a chimeric antibody or a humanized antibody.
7. The method of claim 5 wherein the first binding protein is a monoclonal antibody.
8. The method of claim 7 wherein the monoclonal antibody is antibody 1C9 as produced by hybridoma 1C9 which is deposited with the American Type Culture Collection with Accession Number PTA-8759.
9. The method of claim 5 which further comprises contacting the specimen with a second binding protein that specifically binds to an epitope of a glycoprotein of an influenza A virus, wherein said first binding protein is a capture binding protein and the second binding protein is a detector binding protein that contains or is conjugated to a detectable element.
10. The method of claim 9 wherein at least one of the first and second binding proteins is a monoclonal antibody.
11. The method of claim 9 wherein the first and second binding proteins are monoclonal antibodies.
12. The method of claim 9 wherein the first binding protein is immobilized onto a solid surface.
13. The method of claim 9 wherein the second binding protein contains a radioactive atom, is conjugated to a fluorescent molecule, or is conjugated to an enzyme.
14. A kit for detecting an influenza A virus in a biological specimen which comprises a first binding protein that binds specifically to an epitope of a glycoprotein of an influenza A virus, said first binding protein having substantially the immunological binding characteristics of monoclonal antibody 1C9 together with reagents for the detection of binding of said binding protein to said envelope glycoprotein.
15. The kit of claim 14 which comprises a second binding protein that specifically binds to an epitope of a glycoprotein of an influenza A virus, wherein the first binding protein is a capture binding protein and the second binding protein is a detector binding protein that contains or is conjugated to a detectable element.
16. The kit of claim 15 wherein at least one of the binding proteins is a monoclonal antibody.
17. The kit of claim 15 wherein the first and second binding proteins are monoclonal antibodies.
18. The kit of claim 15 wherein the first binding protein is immobilized onto a solid surface.
19. The kit of claim 15 wherein the second binding protein contains a radioactive atom, is conjugated to a fluorescent molecule, or is conjugated to an enzyme.
20. A method of treating a subject infected with an influenza A virus which comprises administering to said subject a therapeutically effective amount of a binding protein that binds specifically to an epitope of a glycoprotein of an influenza A virus that has substantially the immunological binding characteristics of monoclonal antibody 1C9.
21. The method of claim 20, wherein the binding protein is a recombinant monoclonal antibody, single chain antibody, antibody fragment, chimeric antibody or humanized antibody.
22. The method of claim 20, wherein the binding protein is a recombinant monoclonal antibody comprising the variable region of mAb 1C9.
23. The method of claim 20, further comprising administration of at least one other antibody.
24. The method of claim 20, further comprising administration of at least one neutralization escape mutant antibody.
25. The method of claim 24, wherein the influenza A virus is an H5 subtype of avian influenza virus.
26. The method of claim 25, wherein the avian influenza virus is an H5N1 subtype.
27. A method of protecting a subject from an influenza A virus infection comprising administering to said subject a binding protein that binds specifically to an epitope of a glycoprotein of an influenza A virus that has substantially the immunological binding characteristics of monoclonal antibody 1 C9 in an amount effective to protect the subject from influenza A virus infection.
28. The method of claim 25, wherein the binding protein is a recombinant monoclonal antibody, single chain antibody, antibody fragment, chimeric antibody or humanized antibody.
29. The method of claim 25, wherein the binding protein is a recombinant monoclonal antibody comprising the variable region of mAb 1C9.
30. The method of claim 25, wherein the influenza A virus is an H5 subtype of avian influenza virus.
31. The method of claim 30, wherein the avian influenza virus is an H5N1 subtype.
PCT/SG2008/000499 2008-12-24 2008-12-24 Monoclonal antibodies specific to the fusion peptide from hemagglutinin from influenza a viruses and uses thereof WO2010074656A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU2008365616A AU2008365616A1 (en) 2008-12-24 2008-12-24 Monoclonal antibodies specific to the fusion peptide from hemagglutinin from influenza A viruses and uses thereof
US13/141,160 US8540995B2 (en) 2008-12-24 2008-12-24 Monoclonal antibodies specific to the fusion peptide from hemagglutinin from influenza A viruses and uses thereof
PCT/SG2008/000499 WO2010074656A1 (en) 2008-12-24 2008-12-24 Monoclonal antibodies specific to the fusion peptide from hemagglutinin from influenza a viruses and uses thereof
SG2011045911A SG172333A1 (en) 2008-12-24 2008-12-24 Monoclonal antibodies specific to the fusion peptide from hemagglutinin from influenza a viruses and uses thereof
CN2008801327259A CN102292350A (en) 2008-12-24 2008-12-24 Monoclonal antibodies specific to the fusion peptide from hemagglutinin from influenza a viruses and uses thereof
EP08879238A EP2379591A4 (en) 2008-12-24 2008-12-24 Monoclonal antibodies specific to the fusion peptide from hemagglutinin from influenza a viruses and uses thereof
TW098144590A TW201028166A (en) 2008-12-24 2009-12-23 Monoclonal antibodies specific to the fusion peptide from hemagglutinin from influenza a viruses and uses thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/SG2008/000499 WO2010074656A1 (en) 2008-12-24 2008-12-24 Monoclonal antibodies specific to the fusion peptide from hemagglutinin from influenza a viruses and uses thereof

Publications (1)

Publication Number Publication Date
WO2010074656A1 true WO2010074656A1 (en) 2010-07-01

Family

ID=42288019

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SG2008/000499 WO2010074656A1 (en) 2008-12-24 2008-12-24 Monoclonal antibodies specific to the fusion peptide from hemagglutinin from influenza a viruses and uses thereof

Country Status (7)

Country Link
US (1) US8540995B2 (en)
EP (1) EP2379591A4 (en)
CN (1) CN102292350A (en)
AU (1) AU2008365616A1 (en)
SG (1) SG172333A1 (en)
TW (1) TW201028166A (en)
WO (1) WO2010074656A1 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2582721A1 (en) * 2010-06-17 2013-04-24 Trellis Bioscience, LLC Antibodies useful in passive influenza immuization
US8877200B2 (en) 2012-05-10 2014-11-04 Visterra, Inc. HA binding agents
US9718875B2 (en) 2013-03-14 2017-08-01 Contrafect Corporation Composition and methods based on neutralizing antibodies delivered intranasally for enhanced therapeutic efficacy
US10513553B2 (en) 2015-11-13 2019-12-24 Visterra, Inc. Compositions and methods for treating and preventing influenza
US10639370B2 (en) 2014-02-04 2020-05-05 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
US10654915B2 (en) 2011-12-05 2020-05-19 Trellis Bioscience, Llc Antibodies useful in passive influenza immunization
US11230593B2 (en) 2019-03-25 2022-01-25 Visterra, Inc. Compositions and methods for treating and preventing influenza
US11246928B2 (en) 2014-02-04 2022-02-15 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2687147C (en) * 2007-05-11 2016-08-23 Temasek Life Sciences Laboratory Limited H5 subtype-specific binding proteins useful for h5 avian influenza diagnosis and surveillance
JP2013540425A (en) 2010-08-03 2013-11-07 ザ ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャライゼーション Polypeptide for treating and / or limiting influenza infection
WO2013138259A2 (en) 2012-03-13 2013-09-19 University Of Washington Through Its Center For Commercialization Polypeptides for treating and/or limiting influenza infection
WO2015143339A2 (en) 2014-03-21 2015-09-24 University Of Washington Enhanced influenza hemagglutinin binders
TWI702229B (en) 2014-12-19 2020-08-21 美商再生元醫藥公司 Human antibodies to influenza hemagglutinin
KR20200115517A (en) 2018-01-26 2020-10-07 리제너론 파마슈티칼스 인코포레이티드 Human antibodies to influenza hemagglutinin

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6720409B2 (en) * 1992-09-17 2004-04-13 Takara Shuzo Co., Ltd. Anti-human influenza virus antibody
WO2005021574A2 (en) * 2003-08-26 2005-03-10 Brd, Vertreten Durch Das Bundesministerium Für Gesundheit Und Soziale Sicherung, Letztvertreten Durch Den Präsidenten Des Robert-Koch-Institutes Induction of antiviral neutralizing antibodies in humans and animals
WO2007082734A2 (en) * 2006-01-17 2007-07-26 Creatogen Laboratories Gmbh Influenza vaccine
WO2007089753A2 (en) * 2006-01-26 2007-08-09 Hx Diagnostics, Inc. Monoclonal antibodies binding to avian influenza virus subtype h5 haemagglutinin and uses thereof
US20070243629A1 (en) * 2003-10-20 2007-10-18 Glykos Finland Oy High Affinity Ligands for Influenza Virus and Methods for Their Production
WO2008028946A2 (en) * 2006-09-07 2008-03-13 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
US20080260762A1 (en) * 1992-08-07 2008-10-23 Grey Howard M HLA binding motifs and peptides and their uses
WO2008140415A1 (en) * 2007-05-11 2008-11-20 Temasek Life Sciences Laboratory Limited H5 subtype-specific binding proteins useful for h5 avian influenza diagnosis and surveillance

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080260762A1 (en) * 1992-08-07 2008-10-23 Grey Howard M HLA binding motifs and peptides and their uses
US6720409B2 (en) * 1992-09-17 2004-04-13 Takara Shuzo Co., Ltd. Anti-human influenza virus antibody
WO2005021574A2 (en) * 2003-08-26 2005-03-10 Brd, Vertreten Durch Das Bundesministerium Für Gesundheit Und Soziale Sicherung, Letztvertreten Durch Den Präsidenten Des Robert-Koch-Institutes Induction of antiviral neutralizing antibodies in humans and animals
US20070243629A1 (en) * 2003-10-20 2007-10-18 Glykos Finland Oy High Affinity Ligands for Influenza Virus and Methods for Their Production
WO2007082734A2 (en) * 2006-01-17 2007-07-26 Creatogen Laboratories Gmbh Influenza vaccine
WO2007089753A2 (en) * 2006-01-26 2007-08-09 Hx Diagnostics, Inc. Monoclonal antibodies binding to avian influenza virus subtype h5 haemagglutinin and uses thereof
WO2008028946A2 (en) * 2006-09-07 2008-03-13 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
WO2008140415A1 (en) * 2007-05-11 2008-11-20 Temasek Life Sciences Laboratory Limited H5 subtype-specific binding proteins useful for h5 avian influenza diagnosis and surveillance

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2379591A4 *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2582721A4 (en) * 2010-06-17 2013-11-20 Trellis Bioscience Llc Antibodies useful in passive influenza immuization
KR101849738B1 (en) 2010-06-17 2018-04-17 트렐리스 바이오싸이언스 인코포레이티드 Antibodies useful in passive influenza immunization
EP2582721A1 (en) * 2010-06-17 2013-04-24 Trellis Bioscience, LLC Antibodies useful in passive influenza immuization
US10676520B2 (en) 2010-06-17 2020-06-09 Trellis Bioscience, Llc Antibodies useful in passive influenza immunization
US10654915B2 (en) 2011-12-05 2020-05-19 Trellis Bioscience, Llc Antibodies useful in passive influenza immunization
US8877200B2 (en) 2012-05-10 2014-11-04 Visterra, Inc. HA binding agents
US9096657B2 (en) 2012-05-10 2015-08-04 Visterra, Inc. HA binding agents
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
US12024552B2 (en) 2012-05-10 2024-07-02 Visterra, Inc. Ha binding agents
US10800835B2 (en) 2012-05-10 2020-10-13 Visterra, Inc. HA binding agents
US11827693B2 (en) 2013-03-14 2023-11-28 Contrafect Corporation Composition and methods based on neutralizing antibodies delivered intranasally for enhanced therapeutic efficacy
US9718875B2 (en) 2013-03-14 2017-08-01 Contrafect Corporation Composition and methods based on neutralizing antibodies delivered intranasally for enhanced therapeutic efficacy
US10639370B2 (en) 2014-02-04 2020-05-05 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
US11246928B2 (en) 2014-02-04 2022-02-15 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
US10513553B2 (en) 2015-11-13 2019-12-24 Visterra, Inc. Compositions and methods for treating and preventing influenza
US11230593B2 (en) 2019-03-25 2022-01-25 Visterra, Inc. Compositions and methods for treating and preventing influenza

Also Published As

Publication number Publication date
EP2379591A1 (en) 2011-10-26
US20110256141A1 (en) 2011-10-20
EP2379591A4 (en) 2012-10-17
CN102292350A (en) 2011-12-21
TW201028166A (en) 2010-08-01
SG172333A1 (en) 2011-07-28
US8540995B2 (en) 2013-09-24
AU2008365616A1 (en) 2011-08-11

Similar Documents

Publication Publication Date Title
US8540995B2 (en) Monoclonal antibodies specific to the fusion peptide from hemagglutinin from influenza A viruses and uses thereof
AU2008297594B2 (en) Monoclonal antibodies specific to hemagglutinin and neuraminidase from influenza virus H5-subtype or N1-subtype and uses thereof
AU2007353481B2 (en) H5 subtype-specific binding proteins useful for H5 avian influenza diagnosis and surveillance
US10072070B2 (en) Potent anti-influenza A neuraminidase subtype N1 antibody
EP3348568B1 (en) Monoclonal antibodies targeting neutralizing epitopes on h7 influenza viruses
WO2010110737A1 (en) Monoclonal antibody against a conserved domain of m2e polypeptide in influenza viruses
AU2013224734A1 (en) Monoclonal antibodies specific to hemagglutinin and neuraminidase from influenza virus h5-subtype or n1-subtype and uses thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880132725.9

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08879238

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 13141160

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2011543476

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2626/KOLNP/2011

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2008365616

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2008879238

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2008365616

Country of ref document: AU

Date of ref document: 20081224

Kind code of ref document: A